Helicobacter pylori Gastritis and Peptic Ulcer Disease

Organism/Discovery

Curved/spiral, microaerophilic, Gram-negative. Marshall+Warren identified as ulcer cause (Marshall drank culture to prove Koch’s postulates) — overturned “stress/acid alone” dogma. 2005 Nobel Prize.

Survival Mechanism

UREASE (large quantity) → hydrolyzes urea → ammonia+CO2 → LOCAL acid neutralization around bacterium → protected microenvironment in acidic stomach. Same urease exploited for DIAGNOSIS (rapid urease test, urea breath test) — virulence factor doubles as diagnostic handle. Spiral shape + polar flagella → motility → burrows through mucus layer to near-neutral epithelial surface.

Pathogenesis

Adheres (BabA adhesin) → chronic mucosal inflammation (direct damage + host immune response) → CHRONIC/LIFELONG if untreated (organism persists despite inflammation, not cleared).

Virulence markers of aggressive strains:

cag pathogenicity island: type IV secretion system injects CagA into host cells → disrupts signaling → ↑severe gastritis/ulcer/gastric cancer risk
VacA (vacuolating cytotoxin): epithelial vacuolation/damage

Clinical Manifestations

MOST infected = ASYMPTOMATIC despite chronic inflammation. Extremely common globally (childhood acquisition, tracks socioeconomic/sanitation). Minority develop apparent disease (strain virulence + host response variation).

Diseases:

Chronic gastritis — NEAR-UNIVERSAL underlying finding if infected (symptomatic or not)
Peptic ulcer disease (gastric+duodenal) — DOMINANT identifiable cause worldwide (+ NSAIDs = other major cause, synergistic if both present)
Gastric adenocarcinoma — H. pylori = IARC Group 1/DEFINITE carcinogen, ONLY BACTERIUM with this classification
Gastric MALT lymphoma — REMARKABLE: can REGRESS with eradication ALONE in early disease (antigen-driven growth) — essentially unique among cancers/antibiotic-treatable infections

Laboratory Diagnosis

INVASIVE (endoscopy-based):

Rapid urease test (CLO test): biopsy in urea+pH indicator medium → color change if urease present, hours. Fast, cheap, most common when endoscopy already done.
Histopathology: biopsy special stains (Giemsa, Warthin-Starry, IHC) — visualizes organism + assesses gastritis/malignancy simultaneously. Most informative single test.
Culture: technically demanding (microaerophilic), slow. Reserved for AST after treatment failure, not routine.

NON-INVASIVE:

Urea breath test: ingest ¹³C/¹⁴C-labeled urea → urease splits → labeled CO2 in exhaled breath. Highly sens/spec. PREFERRED for confirming ERADICATION post-treatment.
Stool antigen test: direct antigen detection. Useful initial Dx + eradication confirmation.
Serology (IgG): confirms past/present exposure, CANNOT distinguish active from PRIOR TREATED infection (Ab persists) — UNSUITABLE for confirming treatment success.

Treatment

Triple/quadruple COMBINATION therapy (same multi-drug principle as TB/leprosy — prevents rapid resistance).

Standard triple: PPI + 2 antibiotics (amoxicillin+clarithromycin, OR metronidazole+clarithromycin), 10-14 days.

Bismuth QUADRUPLE (PPI + bismuth subsalicylate + metronidazole + tetracycline): favored 1st-line in high-clarithromycin-resistance areas, OR 2nd-line salvage after triple failure.

Confirm eradication (urea breath test/stool antigen, NOT serology) after treatment — esp. for PUD, MALT lymphoma, ongoing symptoms.

The Organism and a Nobel-Prize-Winning Discovery

Helicobacter pylori is a curved/spiral, microaerophilic, Gram-negative bacillus, genuinely notable for having overturned a longstanding medical dogma: for decades, peptic ulcer disease was assumed to be caused by stress and excess acid alone, with no organism thought capable of surviving the stomach’s hostile acidic environment at all — Barry Marshall and Robin Warren’s identification of H. pylori as the true cause (Marshall famously drinking a culture of the organism himself to prove Koch’s postulates when the scientific community remained sceptical) earned them the 2005 Nobel Prize in Physiology or Medicine, and represents one of the clearest examples in modern medicine of a single organism’s discovery genuinely transforming standard treatment for an extremely common disease.

How H. pylori Survives the Stomach

The organism’s defining survival adaptation is urease — an enzyme produced in large quantity, which hydrolyses host urea into ammonia and carbon dioxide, and the ammonia locally neutralizes gastric acid immediately around the bacterium, creating a protected, near-neutral microenvironment despite sitting within the stomach’s overall highly acidic lumen. This same urease activity is exploited directly for diagnosis (rapid urease test and urea breath test, below) — a genuinely elegant case of a virulence factor doubling as a diagnostic handle. Beyond urease, the organism’s spiral shape and multiple polar flagella give it strong motility, letting it burrow through the protective gastric mucus layer to reach the epithelial surface beneath, where the local pH is closer to neutral and acid exposure is minimized.

Pathogenesis

Once established beneath the mucus layer, H. pylori adheres to gastric epithelial cells (via adhesins such as BabA) and triggers chronic mucosal inflammation through both direct epithelial damage and a sustained host immune/inflammatory response — a genuinely chronic, often lifelong infection if untreated, since the organism is well adapted to persist despite ongoing local inflammation rather than being cleared by it. Two virulence factors mark more aggressive strains: the cag pathogenicity island (encoding a type IV secretion system that injects the CagA protein directly into host epithelial cells, disrupting normal cell signalling and strongly associated with more severe gastritis, peptic ulceration, and gastric cancer risk) and the VacA vacuolating cytotoxin (causing epithelial cell vacuolation and damage directly).

Clinical Manifestations

Most infected individuals remain asymptomatic despite chronic gastric inflammation — infection is extremely common globally (often acquired in childhood, with prevalence strongly tracking socioeconomic conditions and sanitation), yet only a minority ever develop clinically apparent disease, reflecting genuine variation in both bacterial strain virulence and host response. Where disease does develop: chronic gastritis (the near-universal underlying finding in anyone actually infected, whether or not it produces symptoms); peptic ulcer disease (both gastric and duodenal ulcers — H. pylori is the dominant identifiable cause of peptic ulcer disease worldwide, alongside NSAID use as the other major cause, and the two can act synergistically when present together in the same patient); gastric adenocarcinoma (H. pylori is formally classified as a Group 1/definite human carcinogen by IARC, the only bacterium with this classification, reflecting the chronic inflammation-driven carcinogenic pathway); and gastric MALT lymphoma (a genuinely remarkable, distinctive clinical fact — this specific B-cell lymphoma can regress with H. pylori eradication alone in early-stage disease, since the lymphoma’s growth in many cases remains directly antigen-driven by ongoing bacterial presence, a relationship essentially unique among cancers and antibiotic-treatable infections).

Laboratory Diagnosis

Testing splits into invasive (endoscopy-based) and non-invasive methods, and choice depends on whether endoscopy is already indicated for another reason:

Rapid urease test (CLO test) — a gastric biopsy specimen placed in a urea-containing medium with a pH indicator; if H. pylori is present, its urease splits the urea, raising pH and producing a visible colour change, typically within hours — fast, cheap, and the most commonly used test when endoscopy is already being performed.
Histopathology of a gastric biopsy (special stains — Giemsa, Warthin-Starry silver, or immunohistochemistry) directly visualizes the organism and simultaneously assesses the degree of gastritis/any malignant change — the most informative single test but requiring endoscopy and pathology processing time.
Culture is technically demanding (microaerophilic requirements) and slow, so it’s reserved mainly for cases needing antimicrobial susceptibility testing (e.g. after treatment failure), rather than routine diagnosis.
Urea breath test — the patient ingests urea labelled with a non-radioactive (¹³C) or radioactive (¹⁴C) carbon isotope; if H. pylori’s urease is present, it splits the labelled urea, and the labelled CO₂ appears in the patient’s exhaled breath, detected by mass spectrometry or scintillation counting — non-invasive, highly sensitive/specific, and, importantly, also the preferred method to confirm eradication after treatment, since it reflects genuinely active, current infection rather than past exposure.
Stool antigen test — detects H. pylori antigen directly in stool, another genuinely useful non-invasive option for both initial diagnosis and confirming eradication.
Serology (IgG antibody) confirms past or present exposure but cannot distinguish active infection from prior, already-treated infection, since antibody can persist for a long period after successful eradication — a real limitation that makes serology unsuitable for confirming treatment success, in contrast to the breath test and stool antigen test above.

Treatment

Standard therapy is triple or quadruple combination therapy, reflecting the same principle seen with M. tuberculosis and M. leprae — combining multiple agents from the start to prevent the rapid resistance selection that would occur with any single antibiotic against an organism capable of chronic, long-term colonization. Standard triple therapy combines a proton pump inhibitor (reducing acid to both aid symptom relief and improve antibiotic stability/efficacy in the gastric environment) with two antibiotics (commonly amoxicillin plus clarithromycin, or metronidazole plus clarithromycin), typically for 10–14 days. Given rising clarithromycin resistance in many regions, bismuth-based quadruple therapy (a PPI, bismuth subsalicylate, metronidazole, and tetracycline) is increasingly favoured as first-line in areas with known high clarithromycin resistance, or as second-line salvage therapy after triple-therapy failure. Confirming eradication (by urea breath test or stool antigen, not serology, per above) is recommended after treatment, particularly where peptic ulcer disease, MALT lymphoma, or ongoing symptoms warrant confirmation that the causative organism has genuinely been cleared.